Sponsored by:

ACC.09/i2 Summit

Orlando, Florida; March 28-31

Note that some of these links take you to a site outside of CardioSource.
CardioSource does not assume responsibility for content of external sites.

Tuesday March 31 2009

  • Clopidogrel Plus Aspirin vs. Aspirin Alone for Prevention of Vascular Events in Patients With Atrial Fibrillation at High Risk of Stroke (ACTIVE A) – Stuart J. Connolly

  • Effects of Optimal Medical Therapy Alone or in Combination With Cardioverter-Defibrillator Implantation on Survival in Patients Early After Myocardial Infarction (IRIS) – Gerhard Steinbeck

  • Quality of Life Outcomes with Surgical Ventricular Reconstruction in Symptomatic Heart Failure (STICH) – Daniel B. Mark

  • Cardiac Resynchronisation Therapy Prevents Disease Progression in NYHA Class I-II Heart Failure Patients: 24 Months Results From the European Cohort (REVERSE) – Jean-Claude Daubert

Monday March 30 2009

  • Impact of Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction (NAPLES II) – Carlo Briguori

  • Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention (ARMYDA-RECAPTURE) – Germano DiSciascio

  • Endovascular vs. Open Surgical Repair of Thoracic Aortic Disease (TEVAR) – Davy Cheng

  • Immediate vs. Next Day Catheterization in Non-ST Elevation Acute Coronary Syndrome (ABOARD) – Gilles Montalescot

  • The VentrAssist U.S. Pivotal Bridge to Cardiac Transplantation Trial – Andrew J. Boyle

  • Omega-3 Fatty Acids on Top of Modern Therapy After Acute Myocardial Infarction (OMEGA) – Jochen Senges

  • Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (REVIVAL-3) – Ilka Ott

  • Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndromes (EARLY ACS) – L. Kristin Newby

  • Dual Treatment Targets for LDL Cholesterol and C-Reactive Protein After Initiation of Rosuvastatin Therapy (JUPITER) – Paul M. Ridker

  • Continuous Internet Self Reporting vs. Office Monitoring of Blood Pressure for Reducing Cardiovascular Disease Risk – Alfred Bove

  • Examination of Cardiovascular, Metabolic, and Autonomic Changes Associated with the DASH Diet Alone and in Combination with Exercise and Weight Reduction in Hypertensive Men and Women (ENCORE) – Alan L. Hinderliter

  • Effect of Rosuvastatin vs. Placebo on Cardiovascular Outcomes in Patients with End-Stage Renal Disease on Hemodialysis (AURORA) – Bengt Fellstrom

  • Impact of Combinations of Three Blood Pressure Lowering Drugs, a Statin, and Aspirin on Cardiovascular Risk Factors in 2000 Individuals Without Cardiovascular Disease (TIPS) – Salim Yusuf

Sunday March 29 2009

  • Predictors of Stent Thrombosis After Primary Angioplasty in Acute Myocardial Infarction (HORIZONS-AMI) – George D. Dangas

  • Comparison of Sirolimus- and Paclitaxel-Eluting Stents vs Zotarolimus-Eluting Stents in Real World Practice (ZEST) – Seung-Jung Park

  • CABG vs. CABG and Surgical Ventricular Reconstruction (STICH) – Robert H. Jones

  • Cardiac Contractility Modulation in Patients with Advanced Heart Failure (FIX-HF-5) – William T. Abraham

  • Can Pro-Brain Natriuretic Peptide Guided Therapy of Heart Failure Improve Heart Failure Morbidity and Mortality? (PRIMA) – Luc Eurlings

  • Rosuvastatin in the Prevention of Venous Thromboembolism (JUPITER) – Robert J. Glynn

  • Signs of Subclinical Coronary Atherosclerosis Measured as Coronary Artery Calcification Improve Risk Prediction of Hard Events Beyond Traditional Risk Factors in an Unselected General Population (Heinz Nixdorf Recall) – Raimund A. Erbel

  • Utilization of SPECT Myocardial Perfusion Imaging Using the ACCF Appropriateness Criteria: The ACCF and United HealthCare SPECT Pilot Study – Robert C. Hendel

Saturday March 28 2009

  • Randomized, Double-blind Placebo Controlled Phase 2 Study of Intramyocardial Inejction of Autologous CD34+ Cells for Treatment of Refractory Angina – Douglas W. Losordo

  • Genous Stent vs. Chromium-Cobalt Stent for Treatment of ST-Elevation Myocardial Infarction (GENIUS-STEMI) – Pavel Cervinka

  • Percutaneous Left Atrial Appendage Closure vs. Warfarin for Stroke Prevention in Atrial Fibrillation (PROTECT AF) – David R. Holmes, Jr.

  • Health Related Quality of Life and U.S. Based Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery for Patients with 3-Vessel and Left Main Coronary Artery Disease (SYNTAX) – David J. Cohen

  • Outcomes Following Coronary Stenting in a Linked NCDR and CMS Database: A National Study of Long Term, Real-World Outcomes of Bare-Metal and Drug-Eluting Stents – Pamela S. Douglas